- Home
- STLD vs MRNA Comparison
STLD vs MRNA Comparison
Compare STLD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STLD
- MRNA
- Stock Information
- Founded
- STLD 1993
- MRNA 2010
- Country
- STLD United States
- MRNA United States
- Employees
- STLD N/A
- MRNA N/A
- Industry
- STLD Steel/Iron Ore
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STLD Industrials
- MRNA Health Care
- Exchange
- STLD Nasdaq
- MRNA Nasdaq
- Market Cap
- STLD 18.6B
- MRNA 16.0B
- IPO Year
- STLD 1996
- MRNA 2018
- Fundamental
- Price
- STLD $130.71
- MRNA $35.53
- Analyst Decision
- STLD Buy
- MRNA Hold
- Analyst Count
- STLD 12
- MRNA 20
- Target Price
- STLD $144.25
- MRNA $59.65
- AVG Volume (30 Days)
- STLD 1.8M
- MRNA 13.6M
- Earning Date
- STLD 01-22-2025
- MRNA 02-14-2025
- Dividend Yield
- STLD 1.41%
- MRNA N/A
- EPS Growth
- STLD N/A
- MRNA N/A
- EPS
- STLD 9.84
- MRNA N/A
- Revenue
- STLD $17,540,390,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- STLD $3.16
- MRNA N/A
- Revenue Next Year
- STLD $9.32
- MRNA $22.19
- P/E Ratio
- STLD $13.25
- MRNA N/A
- Revenue Growth
- STLD N/A
- MRNA N/A
- 52 Week Low
- STLD $104.60
- MRNA $29.25
- 52 Week High
- STLD $155.56
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- STLD 51.40
- MRNA 48.60
- Support Level
- STLD $129.38
- MRNA $32.78
- Resistance Level
- STLD $139.20
- MRNA $36.98
- Average True Range (ATR)
- STLD 3.92
- MRNA 2.50
- MACD
- STLD 0.22
- MRNA 0.30
- Stochastic Oscillator
- STLD 42.88
- MRNA 66.81
About STLD Steel Dynamics Inc.
Steel Dynamics Inc operates scrap-based steel minimills with roughly 16 million tons of annual steel production capacity. The company's segment includes steel operations, metals recycling operations, steel fabrication operations, Aluminum Operations Segment, and others. It generates maximum revenue from the steel operations segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.